Bio.services provides a custom anti-idiotypic antibody (anti-ID Abs) production and downstream assay services to support your study, preclinical and clinical trials and the development of monoclonal antibody drugs. We are professionals in developing high specificity and affinity monoclonal antibodies from various species (rabbit, chicken, llama, mouse, rat, sheep and human). We have phage display immune antibody library construction and screening methods which are the best method to raise monoclonal antibodies from species that do not have hybridoma technology available. We provide both custom anti-idiotypic antibody production services and products to meet our customers’ needs.

  • Type 1. Anti-idiotypic antibody detecting FREE antibody. (paratope specific, inhibitory, neutralizing, detects free drug)
  • Type 2. Anti-idiotypic antibody detecting TOTAL antibody. (not paratope specific, not inhibitory, detects total drug)
  • Type 3. Anti-idiotypic antibody detecting T cell receptor.

Applications:
• Antibody drug pharmacokinetic/pharmacodynamics (PK/PD) studies: the anti-ID capture Sandwich ELISA and anti-ID antibody bridging
• Antibody drug immunogenicity (immune response, IR) studies
• Preclinical research of therapeutic antibodies
• Anti-drug antibodies (ADA) for clinical development
• Controls in ligand binding neutralizing assays
• Controls in antibody blocking assays

We approaches in developing anti-idiotypic antibodies:

  • Immunized phage display library technology:
    Target antibody in the forms of whole IgG, scFv, Fab or F(ab’)2 or peptides designed according to the sequences of the variable domains is utilized to immunize animals. Isolated immunized antibody library is packaged to phage library and anti-ID antibodies can then be generated by biopanning for 3-4 cycles. scFv/Fab antibodies with an affinity of 10-10 M could be obtained. In vitro selection allows us to use  isotype-matching control antibodies as blockers, to avoid enrichment of antibodies that bind to other regions of the target antibody.

Guarantees:
• Fast turnaround time: 8 weeks
• More than 98% success rate
• High specificity and binding affinity
• Convert to full length immunoglobulin as required isotype
• Long-term, secure supply from preclinical research through to clinical testing
• Readily integrated downstream antibody drug PK/PD and immunogenicity assay development